Protease Inhibitors in Liver Disease
- 1 January 1988
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 23 (5), 620-624
- https://doi.org/10.3109/00365528809093922
Abstract
Measurements of the principal protease inhibitors were carried out in patients with two types of chronic liver disease: alcoholic cirrhosis and primary biliary cirrhosis. Measurement of the two major protease inhibitors operative in the haemostatic mechanism.sbd.that is, antithrombin III and .alpha.2-antiplasmin.sbd.showed signfiicantly reduced levels in the alcoholic cirrhosis group, who satisfied clinical and biochemical criteria of impaired hepatocellular function, but not in the primary biliary cirrhosis group, who had relatively good preservation of hepatocellular function. Significant correlation of levels of both these major protease inhibitors with the serum albumin concentration was also found. No evidence of disseminated intravascular coagulation was detected, and therefore failure of synthesis by the liver is the likely explanation of the low levels noted.This publication has 7 references indexed in Scilit:
- α2antiplasmin and disseminated intravascular coagulation in liver cirrhosisThrombosis Research, 1985
- Plasmin‐a2‐antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysisBritish Journal of Haematology, 1984
- Comparative Studies on Human Activators of PlasminogenBritish Journal of Haematology, 1981
- Congenital Deficiency of α2-Plasmin Inhibitor Associated with Severe Hemorrhagic Tendency *Journal of Clinical Investigation, 1979
- Antithrombin III (AT-III) as a diagnostic aid in disseminated intravascular coagulationThrombosis Research, 1977
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973
- Plasma fibrinogen and plasminogen levels in health and in ischaemic heart diseaseJournal of Clinical Pathology, 1966